Skip to main
DTIL

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences is poised for success as the only company targeting the direct elimination of cccDNA in the competitive landscape of HBV cure therapies, evidenced by the highly differentiated results of their PBGENE-HBV program, including the critical dismantling of the viral replication source. The company's other programs, such as PBGENE-DMD, have shown promising early data and a clear focus on functional restoration rather than mere dystrophin detection, supported by significant preclinical evidence and strong safety profile, positioning the company for future success and potentially transformative advancements in the treatment of DMD. Risks to the company's strong potential lie predominantly in the success of the clinical development and potential commercial launch expenses for their programs, as well as general risks associated with the biopharmaceutical industry.

Bears say

Precision BioSciences is a clinical-stage gene editing company with two highly differentiated gene editing programs currently in development for hepatitis B virus (HBV) and Duchenne muscular dystrophy (DMD). These programs show promise in addressing large patient populations with high unmet needs, but the limited near-term dataset size poses a high-risk/high-reward situation for investors. The company's upcoming key catalyst is the potential nucleos(t)ide-analog (NUC) withdrawal, which will depend heavily on physician alignment and could make or break the programs' success.

Precision Biosciences (DTIL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Precision Biosciences (DTIL) has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.